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and branched devices
Zenia Martin, Roy K. Greenberg, Tara M. Mastracci, Mat-
thew J. Eagleton, Adrian O'Callaghan, James Bena
Objective: Endovascular aneurysm repair (EVAR) will fail
over time in a percentage of patients. Mechanical failure of
the device, progression of aortic disease, or interface
complications between the device and the native vascula-
ture may contribute. Our aim was to evaluate the role of
fenestrated and branched endografts as treatment options
for failed devices.
Methods: Between January 2001 and June 2013, 970
patients were enrolled into a physician-sponsored inves-
tigational device exemption (PSIDE) study and treated with
a fenestrated/branched endograft. All patients treated for
nonurgent proximal neck failure of an infrarenal endo-
prosthesis previously implanted during EVAR comprised the
study group. Patients treated for a primary aneurysm within
the PSIDE were evaluated as a comparison group to identify
preoperative risk factors for failure. A retrospective review
was undertaken to determine the details of the initial EVAR,
whereas the prospective PSIDE database was used to assess
outcomes of secondary treatment. Three-dimensional
imaging techniques were used to deﬁne all morphologic
measurements. Statistical analysis included comparisons
between categoric variables with the c2 test and between
continuous variables with the Wilcoxon rank sum test
between patients with late failures and those with native
aortic repair. Kaplan-Meier curves were used to analyze
overall survival.
Results: Of 970 patients enrolled in the PSIDE, 54 (5.6%)
had late failure of a prior endograft. Fenestrated/branched
devices were used to address the failure in each patient.
The etiology of failure was related to a proximal neck issue
in all patients: type Ia endoleak in 38, stent migration in 18,
neck degeneration in 28, or some combination of these
factors. The endovascular rescue procedure took place a
mean of 61 months after the primary procedure. The mean
aneurysm diameter at reintervention was 67 mm. Patients
requiring a secondary fenestrated procedure were younger
at the time of their primary intervention (P = .039) and
were more likely to have a history of chronic renal insufﬁ-
ciency (P = .05) compared with other patients in the PSIDE.
Technical success rate in the study group was 85% (44 of
52). Successful stenting was achieved in 71 of 77 (92%)
target vessels. Thirty-day mortality was 3.8% (two of 52).*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(14)00240-8Fluoroscopy dose and operating time were longer in the
rescue group (P = .07) than in the control group (P = .008).
Secondary interventions were required in 36.5% (19 of 52)
of patients.
Conclusions: Our series demonstrates the risk for late fail-
ure after EVAR is greater in patients who are younger and
have chronic renal impairment at the time of implantation.
Branched and fenestrated repair after failed EVAR is more
complex than repair in the native aorta. More research is
needed to identify patients at higher risk of failure after
EVAR to prevent the need for rescue in the future.Results of the Anaconda endovascular graft in abdominal
aortic aneurysm with a severe angulated infrarenal neck
Steffan G.J. Rödel, Clark J. Zeebregts, Ad B. Huisman, Robert
H. Geelkerken, on behalf of the Multicenter Angulated Neck
Study with the Anaconda study participants,
Objective: Proximal neck anatomy of an abdominal aortic
aneurysm (AAA), especially a severe angulated neck of more
than 60 degrees, predicts adverse outcome in endovascular
aneurysm repair. In the present study, we evaluate the
feasibility of the use of the Anaconda endovascular graft
(Vascutec, Terumo, Inchinnan, Scotland) for treating
infrarenal AAA with a severe angulated neck (>60 degrees)
and report the midterm outcomes.
Methods: In total, nine Dutch hospitals participated in this
prospective cohort study. From December 2005 to January
2011, a total of 36 AAA patients, 30 men and six women,
were included. Mean and median follow-up were both
40 months.
Results: Mean infrarenal neck angulation was 82 degrees.
Successful deployment was reached in 34 of 36 patients.
Primary technical success was achieved in 30 of 36 patients
(83%). There was no aneurysm-related death. Four-year
primary clinical success was 69%. In the ﬁrst year, eight
clinical failures were reported including four leg occlusions
which could be solved using standard procedures. After the
ﬁrst year, three patients with additional failures occurred;
two of them were leg occlusions. Four patients needed
conversion to open AAA exclusion. In six of 36 patients, one
or more reinterventions were necessary. Three of them
were performed for occlusion of one Anaconda leg and two
were for occlusion of the body.
Conclusions: The use of the Anaconda endovascular graft in
AAA with a severe angulated infrarenal neck is feasible but
has its side effects. Most clinical failures occur in the ﬁrst
year. Thereafter, few problems occur, and midterm results
are acceptable. Summarizing the present experiences, we
700 Abstractsconclude that open AAA repair is still a preferable option in
patients with challenging aortic neck anatomy and ﬁt for
open surgery.Rehospitalization to primary versus different facilities
following abdominal aortic aneurysm repair
Richard S. Saunders, Sara Fernandes-Taylor, Amy J.H. Kind,
Travis L. Engelbert, Caprice C. Greenberg, Maureen A.
Smith, Jon S. Matsumura, K. Craig Kent
Objective: Reducing readmissions represents a unique
opportunity to improve care and reduce health care costs
and is the focus of major payers. A large number of surgical
patients are readmitted to hospitals other than where the
primary surgery was performed, resulting in clinical deci-
sions that do not incorporate the primary surgeon and
potentially alter outcomes. This study characterizes read-
mission to primary vs different hospitals after abdominal
aortic aneurysm (AAA) repair and examines the implications
with regard to mortality and cost.
Methods: Patients who underwent open or endovascular
aneurysm repair for AAA were identiﬁed from the Centers
for Medicare and Medicaid Services Chronic Conditions
Warehouse, a random 5% national sample of Medicare
beneﬁciaries from 2005 to 2009. Outcomes for patients
who underwent AAA repair and were readmitted within
30 days of initial discharge were compared based on
readmission location (primary vs different hospital).
Results: A total of 885 patients underwent AAA repair and
were readmitted within 30 days. Of these, 626 (70.7%)
returned to the primary facility, and 259 (29.3%) returned
to a different facility. Greater distance from patient resi-
dence to the primary hospital was the strongest predictor of
readmission to a different facility. Patients living 50 to 100
miles from the primary hospital were more likely to be
readmitted to a different hospital compared with patients
living <10 miles away (odds ratio, 8.50; P < .001). Patients
with diagnoses directly related to the surgery (eg, wound
infection) were more likely to be readmitted to the primary
hospital, whereas medical diagnoses (eg, pneumonia and
congestive heart failure) were more likely to be treated at a
different hospital. There was no statistically signiﬁcant dif-
ference in mortality between patients readmitted to a dif-
ferent or the primary hospital. Median total 30-day
payments were signiﬁcantly lower at different vs primary
hospitals (primary, $11,978 vs different, $11,168; P = .04).
Conclusions: Readmission to a different facility after AAA
repair is common and occurs more frequently than for the
overall Medicare population. Patients travelling a greater
distance for AAA repair are more likely to return to different
vs the primary hospital when further care is required. For
AAA repair, quality healthcare may be achieved at margin-
ally lower cost and with greater patient convenience for
selected readmissions at hospitals other than where the
initial procedure was performed.The inﬂuence of gender on patency rates after iliac artery
stenting
Beate Bechter-Hugl, Jügen Falkensammer, Olaf Gorny,
Andreas Greiner, Andreas Chemelli, Gustav Fraedrich
Objective: The purpose of this study was to investigate the
inﬂuence of gender on the long-term outcome after iliac
artery stenting and to assess gender-speciﬁc differences of
the inﬂuence of risk factors on treatment success and
patency rates.
Methods: Between January 2000 and December 2006, 404
percutaneous transluminal angioplasties with primary stent
deployment for symptomatic iliac artery occlusive disease
were performed at our center. These included 128 inter-
ventions in women and 276 interventions in men.
Results: Whereas average age was signiﬁcantly higher
(65.9  12.9 years; P = .007) and arterial hypertension more
frequent (60.9% vs 49.3%; P = .032) in women, hyper-
uricemia (7.0% vs 14.1%; P = .047) and a positive smoking
status (61.7% vs 74.3%; P = .014) were more frequently
observed in men. Fontaine stage was more advanced
(stages III and IV) in women than in men (P = .028; P <
.001). Technical success was 97.7% in women and 99.3% in
men. Overall complication rate was higher in women
compared with men (P = .002), mostly caused by access site
hematomas (4.7% vs 0.4%) and pseudoaneurysms (8.6% vs
2.5%). Patients were followed up for 45.0  33.3 months.
Restenosis developed in 16.8% of cases in women and in
14.6% of cases in men and was treated in 73.7% by an
endovascular approach. Primary patency rates at 1, 3, 5,
and 7 years were 90.3%, 77.2%, 60.2%, and 46.4% in
women and 89.9%, 71.5%, 63.6%, and 59.7% in men,
respectively (P = .524; log-rank, .406). Secondary patency
rates were 97.2%, 91%, 81.5%, and 70.3% in women and
97.1%, 89.1%, 82.6%, and 78% in men, respectively (P =
.959; log-rank, .003). Multivariate analysis identiﬁed lower
age as the only independent risk factor for recurrent disease
in both groups. Age-deﬁned subgroup analysis showed a
restenosis/reocclusion rate of 23.9% in men and 22.1% in
women older than 63.5 years (P = .861) but 32.1% in men
and 49.1% in women younger than that (P = .034).
Conclusions: Our data suggest that although women are
older and present with a more advanced stage of peripheral
arterial occlusive disease, endovascular therapy is equally
effective irrespective of gender. Surprisingly, the subgroup
of young female patients had a speciﬁcally poor outcome.Cilostazol is associated with improved outcomes after
peripheral endovascular interventions
Courtney J. Warner, Spencer W. Greaves, Robin J. Larson,
David H. Stone, Richard J. Powell, Daniel B. Walsh, Philip P.
Goodney
Objective: Although cilostazol is commonly used as an
adjunct after peripheral vascular interventions, its efﬁcacy
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outcomes after peripheral vascular interventions using
meta-analytic techniques.
Methods: We searched MEDLINE (1946-2012), Cochrane
CENTRAL (1996-2012), and trial registries for studies com-
paring cilostazol in combination with antiplatelet therapy to
antiplatelet therapy alone after peripheral vascular inter-
ventions. Treatment effects were reported as pooled risk/
hazard ratio (HR) with random-effects models.
Results: Two randomized trials and four retrospective
cohorts involving 1522 patients met inclusion criteria.
Across studies, mean age ranged from 65 to 76 years, and
the majority of patients were male (64%-83%); mean fol-
low-up ranged from 18 to 37 months. Most interventions
were in the femoropopliteal segment, and overall, 68% of
patients had stents placed. Pooled estimates demonstrated
that the addition of cilostazol was associated with
decreased restenosis (relative risk [RR], 0.71; 95% con-
ﬁdence interval [CI], 0.60-0.84; P < .001), improved
amputation-free survival (HR, 0.63; 95% CI, 0.47-0.85; P =
.002), improved limb salvage (HR, 0.42; 95% CI, 0.27-0.66;
P < .001), and improved freedom from target lesion
revascularization (RR, 1.36; 95% CI, 1.14-1.61; P < .001).
There was no signiﬁcant reduction in mortality among those
receiving cilostazol (RR, 0.73; 95% CI, 0.45-1.19; P = .21).
Conclusions: The addition of cilostazol to antiplatelet ther-
apy after peripheral vascular interventions is associated
with a reduced risk of restenosis, amputation, and target
lesion revascularization in our meta-analysis of six studies.
Consideration of cilostazol as a medical adjunct after
peripheral vascular interventions is warranted, presuming
these ﬁndings are broadly generalizable.Comparison of military and civilian popliteal artery trauma
outcomes
Anahita Dua, Bhavin Patel, Sapan S. Desai, John B. Holcomb,
Charles E. Wade, Sheila Coogan, Charles J. Fox
Objective: Popliteal artery injury has historically led to high
amputation rates in both the military and civilian setting.
Military and civilian popliteal injury patterns differ in
mechanism and severity of injury, prompting us to compare
modern management and report differences in outcomes
between these two patient groups. We hypothesized that
whereas amputation rates may be higher in the military, this
would correlate with worse overall injury severity.
Methods: Military casualties from 2003-2007 with a pop-
liteal artery injury identiﬁed from the Joint Theater Trauma
Registry were compared retrospectively with civilian
patients presenting to a single level I institution from 2002-
2009 with popliteal arterial injury. Demographics, mecha-
nism of injury, coinjuries, Injury Severity Score (ISS), Man-
gled Extremity Severity Scores (MESS), interventions, and
secondary amputation rates were reviewed. Descriptive
statistics and unpaired t-tests were used to compare data.
Statistical signiﬁcance was P < .05.Results: The study group of 110 patients consisted of 46
(41.8%) military and 64 (58.2%) civilians with 48 and 64
popliteal artery injuries, respectively. The military pop-
ulation was younger (28 vs 35 years; P < .004), entirely male
(46 [100%] vs 51 [80%]; P < .0001), and had more pene-
trating injuries (44 [96%] vs 19 [30%]; P < .0001). ISS (18.7
vs 13.9; P < .005) and MESS (7.3 vs 5.1; P < .0001) were
higher in the military group. Limb revascularizations in both
military and civilian populations were mostly by autogenous
bypass (65% vs 77%) followed by primary repair (26% vs
16%), covered stent (0% vs 6%), or other procedure (ligation
and/or thrombectomy) (9% vs 1%). Fasciotomy (20 [42%] vs
37 [58%]; P = .14), compartment syndrome (10 [21%] vs 15
[23%]; P = .84), and concomitant venous repair rates (14
[29%] vs 15 [23%]; P = .42) were not different between
cohorts. There was no difference in the fracture rate (26
[54%] vs 41 [64%]; P = .43), but the civilian group had a
higher rate of dislocation (1 [2%] vs 19 [30%]; P < .0001).
Secondary amputation rates were signiﬁcantly higher in the
military (14 [29%] vs 8 [13%]; P < .03).
Conclusions: Although both civilian and military cohorts
have high amputation rates for popliteal arterial injury, the
rate of amputation appears to be higher in the military and
is associated with a penetrating mechanism of injury pri-
marily from improvised explosive devices resulting in a
higher MESS and ISS.Impact of cumulative intravascular contrast exposure on
renal function in patients with occlusive and aneurysmal
vascular disease
Panos Kougias, Sherene Sharath, Neal R. Barshes, Briauna
Lowery, Andrea Garcia, Taemee Pak, Carlos F. Bechara,
George Pisimisis
Objective: Patients with occlusive or aneurysmal vascular
disease are repeatedly exposed to intravascular (IV) con-
trast for diagnostic or therapeutic purposes. We sought to
determine the long-term impact of cumulative iodinated IV
contrast exposure (CIVCE) on renal function; the latter was
deﬁned by means of National Kidney Foundation (NKF)
criteria.
Methods: We performed a longitudinal study of consec-
utive patients without renal insufﬁciency at baseline (NFK
stage I or II) who underwent interventions for arterial
occlusive or aneurysmal disease. We collected detailed data
on any IV iodinated contrast exposure (including diagnostic
or therapeutic angiography, cardiac catheterization, IV
pyelography, computed tomography with IV contrast,
computed tomographic angiography); medication exposure
throughout the observation period; comorbidities; and
demographics. The primary end point was the development
of renal failure (RF) (deﬁned as NFK stage 4 or 5). Analysis
was performed with the use of a shared frailty model with
clustering at the patient level.
Results: Patients (n = 1274) had a mean follow-up of 5.8
(range, 2.2-14) years. In the multivariate model with RF as
702 Abstractsthe dependent variable and after adjusting for the statisti-
cally signiﬁcant covariates of baseline renal function (hazard
ratio [HR], 0.95; P < .001), diabetes (HR, 1.8; P = .007), use
of an angiotensin-converting enzyme inhibitor (HR, 0.63; P =
.03), use of antiplatelets (HR, 0.5; P = .01), cumulative
number of open vascular operations performed (HR, 1.2; P =
.001), and congestive heart failure (HR, 3.2; P < .001), CIVCE
remained an independent predictor for RF development
(HR, 1.1; P < .001). In the multivariate survival analysis
model and after adjusting for the statistically signiﬁcant
covariates of perioperative myocardial infarction (HR, 3.9;
P < .001), age at entry in the cohort (HR, 1.05; P = .035),
total number of open operations (HR, 1.51; P < .001), and
serum albumin (HR, 0.47; P < .001), CIVCE was an inde-
pendent predictor of death (HR, 1.07; P < .001).
Conclusions: Cumulative IV contrast exposure is an inde-
pendent predictor of RF and death in patients with occlu-
sive and aneurysmal vascular disease.Efﬁcacy of axillary-to-femoral vein bypass in relieving
venous hypertension in dialysis patients with symptomatic
central vein occlusion
Joshua C. Grimm, Robert J. Beaulieu, Ibrahim S. Sultan,
Mahmoud B. Malas, Thomas Reifsnyder
Objective: Central vein stenosis or occlusion remains an
unfortunate complication associated with the use of dialysis
catheters. In patients with a functioning arteriovenous ﬁs-tula, central vein stenosis can lead to debilitating arm,
breast, or neck swelling. Treatment typically involves central
vein angioplasty or stenting, or both, but restenosis and
reocclusion rates remain high. Presented here are the initial
results of a unique series of patients with a mature arte-
riovenous access and symptomatic upper extremity venous
hypertension who were treated with axillary vein-to-femo-
ral vein bypass after endovascular therapy failed.
Methods: This was a retrospective analysis of 10 hemo-
dialysis patients with a functioning right upper extremity
access who underwent axillary vein-to-femoral vein bypass
between December 2011 and April 2013.
Results: The 10 patients (seven men) were a median age of
58 years. All patients had documentation of prior central
venous catheter placement and had undergone a previous
endovascular procedure that was unsuccessful or technically
unfeasible. The median hospital stay was 2 days (range, 1-
3 days), and the median assisted-primary patency was
197 days (25th-75th percentile, 114-240 days). Three patients
presented with recurrent arm swelling that was successfully
managed in one patient with revision of the proximal anas-
tomosis.Three additional patients presentedwith subsequent
lower extremity swelling, with one patient beneﬁtting from
femoral vein angioplasty. Ultimately, six patients continued to
use their original access, and two required placement of
interval central venous catheters for hemodialysis.
Conclusions: In patients who have exhausted all endovas-
cular options, axillary-to-femoral vein bypassmay represent a
safe and efﬁcacious approach to alleviate extremity swelling
while simultaneously salvaging a functional dialysis access.
